Jazz Pharmaceuticals’ (JAZZ) Overweight Rating Reaffirmed at Piper Sandler
Piper Sandler reaffirmed their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report ...
Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab
Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates. I continue to see Jazz stock as a valuation ...
FiercePharma4d
Jazz 'active and looking' at M&A deals of 'various sizes' as it wraps up Epidiolex patent fights: execs
Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd brought ...
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 Sales
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.5% ...
StockStory.org on MSN6d
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow after the bell. Here’s what to look ...
Jazz Pharmaceuticals price target raised to $205 from $195 at TD Cowen
TD Cowen raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $205 from $195 and keeps a Buy rating on the shares. The firm said Q4 ...
ETF Daily News1d
Jazz Pharmaceuticals (NASDAQ:JAZZ) Cut to Neutral at Cantor Fitzgerald
Cantor Fitzgerald cut shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) from an overweight rating to a neutral rating in a report published on Wednesday, Marketbeat Ratings reports.
Jazz: Q4 Earnings Snapshot
Jazz expects full-year earnings in the range of $22.50 to $24 per share, with revenue in the range of $4.15 billion to $4.4 billion. This story was generated by Automated Insights ( ...
Jazz Pharmaceuticals price target raised to $200 from $190 at Barclays
Barclays analyst Balaji Prasad raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $200 from $190 and keeps an Overweight rating ...
Jazz Pharmaceuticals plc Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
It's been a good week for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shareholders, because the company has just released its latest yearly results, and the shares gained 4.8% to US$143. The result was ...